<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673617</url>
  </required_header>
  <id_info>
    <org_study_id>AB-101-01</org_study_id>
    <nct_id>NCT04673617</nct_id>
  </id_info>
  <brief_title>AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Artiva Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Artiva Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AB-101 is an off-the shelf, allogeneic cell product made of &quot;natural killer&quot; cells, also&#xD;
      called NK cells. White blood cells are part of the immune system and NK cells are a type of&#xD;
      white blood cell that are known to kill cancer cells.&#xD;
&#xD;
      This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test&#xD;
      the safety of AB-101 given alone or in combination with rituximab. The primary objective of&#xD;
      Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with&#xD;
      relapsed/refractory Non-Hodgkin lymphoma of B-cell origin.&#xD;
&#xD;
      Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of&#xD;
      overall health and tumor response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AB-101 as monotherapy based on adverse events (AEs) (Primary outcome for Phase 1)</measure>
    <time_frame>From the time of consent through End of Study (up to 7 months)</time_frame>
    <description>Incidence of AEs and serious AEs (SAEs) by severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AB-101 in combination with rituximab based on adverse events (AEs) (Primary outcome for Phase 2)</measure>
    <time_frame>From the time of consent through End of Study (up to 7 months)</time_frame>
    <description>Incidence of AEs and serious AEs (SAEs) by severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) of AB-101 in combination with rituximab (Primary outcome for Phase 2)</measure>
    <time_frame>From the time of first study drug dose through End of Study (up to 6 months)</time_frame>
    <description>ORR is assessed using the Lugano classification criteria and is defined as the proportion of patients with a documented complete response or partial response (CR + PR) in the absence of earlier disease progression.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-101</intervention_name>
    <description>NK cell therapy</description>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Anti-CD20 antibody therapy</description>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Immune cytokine</description>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lymphodepleting chemotherapy</description>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lymphodepleting chemotherapy</description>
    <arm_group_label>Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)</arm_group_label>
    <arm_group_label>Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)</arm_group_label>
    <arm_group_label>Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of indolent or aggressive NHL of B-cell origin&#xD;
&#xD;
          -  Patient must have progressed or demonstrated intolerance to at least two lines of&#xD;
             FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody&#xD;
             therapy. Prior hematopoietic stem cell transplantation or treatment with FDA-approved&#xD;
             CAR-T therapy is permitted.&#xD;
&#xD;
          -  Patient must have disease that allows for response assessment using the Lugano&#xD;
             Classification criteria.&#xD;
&#xD;
          -  For Group 2 patients, confirmed CD20-positive disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active CNS lymphoma or CNS involvement&#xD;
&#xD;
          -  Cardiac impairment with symptoms of New York Heart Association Classification of III&#xD;
             or IV&#xD;
&#xD;
          -  Cardiac ejection fraction of &lt; 45% on echocardiogram or MUGA scan at screening&#xD;
             assessment&#xD;
&#xD;
          -  Inadequate pulmonary function&#xD;
&#xD;
          -  History of a solid organ allograft, or an inflammatory or autoimmune disease likely to&#xD;
             be exacerbated by IL-2&#xD;
&#xD;
          -  Ongoing uncontrolled systemic infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Litten, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Artiva Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AB-101-01 trial operations</last_name>
    <phone>858-267-4491</phone>
    <email>ab-101-01-study-team@artivabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitkumar Mehta, MD</last_name>
      <phone>205-966-8400</phone>
      <email>amitkumarmehta@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Maroge</last_name>
      <phone>858-246-0682</phone>
      <email>jmaroge@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Ayad Hamdan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rush Cancer Center Clinical Trials Office</last_name>
      <phone>312-CANCER1 (312-226-2371)</phone>
      <email>cancer_studies@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norton Cancer Institute Hematology</last_name>
      <phone>502-899-3366</phone>
      <email>Heme-NCIResearch@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Maly, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OHSU Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Saultz, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Khanal, M.D.</last_name>
      <phone>215-728-4300</phone>
      <email>Rashmi.Khanal@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Rashmi Khanal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

